lncRNA HCG11 suppresses cell proliferation in hormone receptor-positive breast cancer via SRSF1/β-catenin

Hormone receptor positive (HR-positive) breast cancer (BC) is the most common subtype of breast cancer. Despite adjuvant endocrine therapy and chemotherapy-based treatment, the therapeutic response is often not satisfactory in HR-positive BC patients. Therefore, elucidating the mechanisms that regulate the progression of HR-positive BC is urgently required to identify new therapeutic targets. Previously, HLA Complex Group 11 (HCG11), located on the major histocompatibility complex (MHC) region, was found to be abnormally expressed in a variety of tumor cells. However, the role of HCG11 in HR-positive BC cells has not been explored to date. In the current study, we found that HCG11 is downregulated in HR-positive BC tissues and cell lines. Both in vitro and in vivo, HCG11 acts as a tumor suppressor in HR-positive BC cells. Furthermore, the mechanistic details unraveled that HCG11 recruits Serine/arginine-rich splicing factor 1 (SRSF1) to target β-catenin mRNA for promoting the translation of β-catenin. Our study emphasizes the potential of HCG11 as a novel intervention target for HR-positive BC treatment.

[1]  L. Ming,et al.  LncRNA HCG11 Facilitates Nasopharyngeal Carcinoma Progression Through Regulating miRNA-490-3p/MAP3K9 Axis , 2022, Frontiers in Oncology.

[2]  Lin Fang,et al.  CircRPAP2 regulates the alternative splicing of PTK2 by binding to SRSF1 in breast cancer , 2022, Cell death discovery.

[3]  Hongming Song,et al.  EIF4A3-mediated circPRKCI expression promotes triple-negative breast cancer progression by regulating WBP2 and PI3K/AKT signaling pathway , 2022, Cell death discovery.

[4]  Lin Fang,et al.  MiR-181c suppresses triple-negative breast cancer tumorigenesis by targeting MAP4K4 , 2022, Pathology - Research and Practice.

[5]  Gang Yin,et al.  Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities , 2022, Signal Transduction and Targeted Therapy.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  Min Ling,et al.  The Curcumin Analog EF24 Inhibits Proliferation and Invasion of Triple-Negative Breast Cancer Cells by Targeting the Long Noncoding RNA HCG11/Sp1 Axis , 2021, Molecular and cellular biology.

[8]  Liling Guo,et al.  LncRNA HCG11 mediated by METTL14 inhibits the growth of lung adenocarcinoma via IGF2BP2/LATS1. , 2021, Biochemical and biophysical research communications.

[9]  Yang Zhang,et al.  The role and mechanism of HLA complex group 11 in cancer. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[10]  Jie Gu,et al.  lncRNA HCG11 suppresses human osteosarcoma growth through upregulating p27 Kip1 , 2021, Aging.

[11]  Chen-zhou Wu,et al.  Wnt/β-catenin signaling in cancers and targeted therapies , 2021, Signal Transduction and Targeted Therapy.

[12]  Yibing Chen,et al.  lncRNA and breast cancer: Progress from identifying mechanisms to challenges and opportunities of clinical treatment , 2021, Molecular therapy. Nucleic acids.

[13]  Bin Zhang,et al.  SRSF1 promotes the inclusion of exon 3 of SRA1 and the invasion of hepatocellular carcinoma cells by interacting with exon 3 of SRA1pre-mRNA , 2021, Cell death discovery.

[14]  P. Zhu,et al.  Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1 , 2021, Journal of Experimental & Clinical Cancer Research.

[15]  Lin Fang,et al.  The Role of miR-640: A Potential Suppressor in Breast Cancer via Wnt7b/β-catenin Signaling Pathway , 2021, Frontiers in Oncology.

[16]  I. Cavalli,et al.  So alike yet so different. Differential expression of the long non-coding RNAs NORAD and HCG11 in breast cancer subtypes , 2021, Genetics and molecular biology.

[17]  Shao-jian Lin,et al.  LncRNA-HCG18 regulates the viability, apoptosis, migration, invasion and epithelial-mesenchymal transition of papillary thyroid cancer cells via regulating the miR-106a-5p/PPP2R2A axis. , 2021, Pathology, research and practice.

[18]  Ya Zhang,et al.  Targeting the Wnt/β-catenin signaling pathway in cancer , 2020, Journal of Hematology & Oncology.

[19]  Xuemei Zhang,et al.  Serine/arginine-rich splicing factors: the bridge linking alternative splicing and cancer , 2020, International journal of biological sciences.

[20]  M. Taheri,et al.  In silico identification of MAPK14-related lncRNAs and assessment of their expression in breast cancer samples , 2020, Scientific Reports.

[21]  Wuzhu Lu,et al.  Long noncoding RNA HCG22 suppresses proliferation and metastasis of bladder cancer cells by regulation of PTBP1 , 2020, Journal of cellular physiology.

[22]  Jianxiang Wang,et al.  LncRNA HCG11 promotes proliferation and migration in gastric cancer via targeting miR-1276/CTNNB1 and activating Wnt signaling pathway , 2019, Cancer Cell International.

[23]  N. Sakunrangsit,et al.  Plumbagin inhibits cancer stem-like cells, angiogenesis and suppresses cell proliferation and invasion by targeting Wnt/β-catenin pathway in endocrine resistant breast cancer. , 2019, Pharmacological research.

[24]  Jerzy K. Kulski,et al.  Genomic Diversity of the Major Histocompatibility Complex in Health and Disease , 2019, Cells.

[25]  A. Di Leo,et al.  The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. , 2019, Cancer treatment reviews.

[26]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[27]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[28]  Y. Mo,et al.  LncRNA-mediated regulation of cell signaling in cancer , 2017, Oncogene.

[29]  S. Fuqua,et al.  Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. , 2016, Current opinion in pharmacology.

[30]  B. Seliger.  Molecular mechanisms of HLA class I‐mediated immune evasion of human tumors and their role in resistance to immunotherapies , 2016, HLA.

[31]  Shuying Sun,et al.  SRSF1-Regulated Alternative Splicing in Breast Cancer. , 2015, Molecular cell.

[32]  C. Sotiriou,et al.  Luminal breast cancer: from biology to treatment , 2013, Nature Reviews Clinical Oncology.

[33]  Zhen Shi,et al.  SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling-mediated tumorigenesis by enhancing β-catenin biosynthesis , 2013, EMBO molecular medicine.

[34]  L. Twyffels,et al.  Shuttling SR proteins: more than splicing factors , 2011, The FEBS journal.